File this under “When is a bargain not really a bargain?”
Three months ago, the Food and Drug Administration approved a generic version of the EpiPen allergy-relief device and made a point of noting the new product from Teva Pharmaceutical (TEVA) would offer a “lower-cost option.” But Teva is not offering the sort of alternative the agency envisioned: Its $300 list price is the same that Mylan (MYL) charges for its so-called authorized generic EpiPen.
The pricing appears to undercut a notion promoted by FDA officials that approving more generics can help relieve the pocketbook pressure many Americans feel over the cost of their medicines. In announcing the approval last August, FDA Commissioner Scott Gottlieb noted that such moves were part of an “overarching effort to remove barriers” to access to “critically important” drugs.
What they really need is an epi-pen with a new design. The current one is too large and awkwardly shaped to carry in your pocket without looking a bit too “happy” to see everyone 🙁
Auvi-Q from kaleo has a great alternative form factor. Carried in a pocket, it would look like a flip phone. Also, it will talk someone through how to use the device, in case the user is incapacitated.
I have no interest in the company/product other than it is what my daughter carries and has had to use once. She even got to train the local EMT/fire department on the device after they showed up at her school.
adamis symjepi is smaller more reliable easier to use will cost less.
Sandoz is going to launch soon.
But then you can buy them retail in the UK for approx $60.
Get yourself a pen-pal !!!!
May I observe that, strictly speaking, the TEVA offering is cheaper than “the EpiPen?” We shall see what impact a third entrant will cause … when there is one.
Comments are closed.